LexAurum Advisors LLC Has $9.83 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

LexAurum Advisors LLC trimmed its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 4.6% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 55,449 shares of the company’s stock after selling 2,681 shares during the period. Johnson & Johnson accounts for 3.2% of LexAurum Advisors LLC’s portfolio, making the stock its 6th largest position. LexAurum Advisors LLC’s holdings in Johnson & Johnson were worth $9,827,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently made changes to their positions in JNJ. Patron Partners LLC grew its stake in Johnson & Johnson by 12.7% during the 1st quarter. Patron Partners LLC now owns 6,625 shares of the company’s stock worth $1,174,000 after buying an additional 747 shares during the last quarter. Tandem Investment Advisors Inc. grew its stake in Johnson & Johnson by 4.8% during the 1st quarter. Tandem Investment Advisors Inc. now owns 326,505 shares of the company’s stock worth $57,867,000 after buying an additional 15,003 shares during the last quarter. Argent Advisors Inc. grew its stake in Johnson & Johnson by 6.6% during the 1st quarter. Argent Advisors Inc. now owns 19,772 shares of the company’s stock worth $3,504,000 after buying an additional 1,218 shares during the last quarter. Exeter Financial LLC grew its stake in Johnson & Johnson by 3.2% during the 1st quarter. Exeter Financial LLC now owns 26,431 shares of the company’s stock worth $4,684,000 after buying an additional 819 shares during the last quarter. Finally, Fusion Capital LLC grew its stake in Johnson & Johnson by 7.8% during the 1st quarter. Fusion Capital LLC now owns 27,844 shares of the company’s stock worth $4,935,000 after buying an additional 2,019 shares during the last quarter. 68.78% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the transaction, the executive vice president now owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CAO Robert J. Decker sold 8,462 shares of the company’s stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the transaction, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the transaction, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The disclosure for this sale can be found here. 0.35% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several brokerages recently weighed in on JNJ. SVB Leerink dropped their target price on Johnson & Johnson from $200.00 to $194.00 in a research note on Wednesday, July 20th. Daiwa Capital Markets assumed coverage on Johnson & Johnson in a research note on Wednesday, June 22nd. They set an “outperform” rating on the stock. Citigroup dropped their price target on Johnson & Johnson from $205.00 to $201.00 in a research note on Wednesday, July 20th. Wells Fargo & Company boosted their price target on Johnson & Johnson from $190.00 to $195.00 and gave the company an “overweight” rating in a research note on Wednesday, July 13th. Finally, UBS Group dropped their price target on Johnson & Johnson from $185.00 to $180.00 in a research note on Thursday, July 21st. Four research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $189.89.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $171.11 on Friday. The stock has a market cap of $449.88 billion, a PE ratio of 24.91, a price-to-earnings-growth ratio of 3.32 and a beta of 0.59. The business has a 50-day simple moving average of $175.21 and a 200-day simple moving average of $174.55. The company has a quick ratio of 1.14, a current ratio of 1.42 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.57 by $0.02. The business had revenue of $24.02 billion during the quarter, compared to analysts’ expectations of $23.85 billion. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.48 EPS. On average, equities analysts expect that Johnson & Johnson will post 10.05 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd will be issued a $1.13 dividend. The ex-dividend date of this dividend is Monday, August 22nd. This represents a $4.52 dividend on an annualized basis and a yield of 2.64%. Johnson & Johnson’s payout ratio is 65.79%.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.